STRATEC Biomedical AG (DE:SBS)
XETRA:SBS
Holding DE:SBS?
Track your performance easily

STRATEC Biomedical (SBS) Income Statement

3 Followers

STRATEC Biomedical Income Statement

Last quarter (Q4 2022), STRATEC Biomedical's total revenue was €66.97M, an increase of 8.17% from the same quarter last year. In Q4, STRATEC Biomedical's net income was €4.50M. See STRATEC Biomedical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
€ 274.63M€ 274.63M€ 287.33M€ 250.10M€ 214.16M€ 187.82M
Cost of Revenue
€ 195.13M€ 195.13M€ 199.62M€ 181.11M€ 163.26M€ 139.59M
Gross Profit
€ 79.49M€ 79.49M€ 87.71M€ 68.99M€ 50.90M€ 48.23M
Operating Expense
€ 36.74M€ 36.74M€ 37.26M€ 34.93M€ 32.69M€ 32.85M
Operating Income
€ 42.75M€ 42.75M€ 50.45M€ 34.06M€ 18.21M€ 15.38M
Net Non Operating Interest Income Expense
€ -1.78M€ -1.78M€ -1.32M€ -1.07M€ -945.00K€ -628.00K
Other Income Expense
------
Pretax Income
€ 39.09M€ 39.09M€ 46.83M€ 33.02M€ 16.48M€ 14.09M
Tax Provision
€ 9.87M€ 9.87M€ 6.87M€ 4.59M€ 2.22M€ 2.98M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
€ 29.22M€ 29.22M€ 39.96M€ 25.18M€ 14.44M€ 8.97M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
€ 231.88M€ 231.88M€ 236.89M€ 216.04M€ 195.95M€ 172.44M
Net Income From Continuing And Discontinued Operation
€ 29.22M€ 29.22M€ 39.96M€ 25.18M€ 14.44M€ 8.97M
Normalized Income
€ 29.22M€ 29.82M€ 42.11M€ 27.01M€ 14.06M€ 11.85M
Interest Expense
€ 1.90M€ 1.90M€ 1.43M€ 1.11M€ 974.00K€ 662.00K
EBIT
€ 40.99M€ 40.99M€ 48.26M€ 34.13M€ 17.46M€ 14.75M
EBITDA
€ 57.92M€ 57.92M€ 66.52M€ 56.72M€ 36.20M€ 36.40M
Currency in EUR

STRATEC Biomedical Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis